|Articles|September 26, 2018
Catalent Selected to Provide Oral Delivery Systems
Advertisement
GB Sciences, Inc. and Catalent Pharma Solutions, a global provider of delivery technologies and development solutions, announced that GB Sciences has selected Catalent to provide oral delivery systems, formulation development, and clinical-scale oral dose manufacturing of GB Sciences’ proprietary active pharmaceutical ingredients for its Parkinson’s disease therapies.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Clinical Trials in 2026: Platformization, AI Fluency, and the Redrawing of the Value Chain
2
FDA Issues Draft Guidance to Advance Bayesian Methods in Clinical Trials
3
Breaking Out of AI Pilot Mode in Clinical Development
4
ACT Brief: Community Sites Prove Readiness, Platformization Reshapes Clinical Ops, and AI Targets Precision Care at JPM
5